These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 21946897)

  • 1. Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7).
    Curto TM; Lagier RJ; Lok AS; Everhart JE; Rowland CM; Sninsky JJ;
    Pharmacogenet Genomics; 2011 Dec; 21(12):851-60. PubMed ID: 21946897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.
    Fontana RJ; Dienstag JL; Bonkovsky HL; Sterling RK; Naishadham D; Goodman ZD; Lok AS; Wright EC; Su GL;
    Gut; 2010 Oct; 59(10):1401-9. PubMed ID: 20675691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?
    Singal AG; Nehra M; Adams-Huet B; Yopp AC; Tiro JA; Marrero JA; Lok AS; Lee WM
    Am J Gastroenterol; 2013 Mar; 108(3):425-32. PubMed ID: 23337478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design.
    Jiménez-Sousa MÁ; Gómez-Moreno AZ; Pineda-Tenor D; Medrano LM; Sánchez-Ruano JJ; Fernández-Rodríguez A; Artaza-Varasa T; Saura-Montalbán J; Vázquez-Morón S; Ryan P; Resino S
    PLoS One; 2018; 13(5):e0197115. PubMed ID: 29742149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppressor of Cytokine Signaling-3 Gene Polymorphisms and the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients in Egypt.
    El Sharnoby A; Bedair HM; Raia GYS; Hamed N; Sabry A; Khalaf FA; Abd Elhamed MR; Abdel-Samiee M
    Asian Pac J Cancer Prev; 2023 Dec; 24(12):4253-4261. PubMed ID: 38156861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of
    Jiménez-Sousa MÁ; Gómez-Moreno AZ; Pineda-Tenor D; Sánchez-Ruano JJ; Artaza-Varasa T; Martin-Vicente M; Fernández-Rodríguez A; Martínez I; Resino S
    Biomolecules; 2019 Apr; 9(4):. PubMed ID: 30970632
    [No Abstract]   [Full Text] [Related]  

  • 7. Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma.
    Singal AG; Mukherjee A; Elmunzer BJ; Higgins PD; Lok AS; Zhu J; Marrero JA; Waljee AK
    Am J Gastroenterol; 2013 Nov; 108(11):1723-30. PubMed ID: 24169273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C.
    Huang CF; Huang CI; Yeh ML; Wang SC; Chen KY; Ko YM; Lin CC; Tsai YS; Tsai PC; Lin ZY; Chen SC; Dai CY; Huang JF; Chuang WL; Yu ML
    Oncotarget; 2017 May; 8(20):32618-32625. PubMed ID: 28427234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial.
    Freedman ND; Curto TM; Morishima C; Seeff LB; Goodman ZD; Wright EC; Sinha R; Everhart JE;
    Aliment Pharmacol Ther; 2011 Jan; 33(1):127-37. PubMed ID: 21083592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C.
    Fontana RJ; Sanyal AJ; Ghany MG; Lee WM; Reid AE; Naishadham D; Everson GT; Kahn JA; Di Bisceglie AM; Szabo G; Morgan TR; Everhart JE;
    Gastroenterology; 2010 Jun; 138(7):2321-31, 2331.e1-2. PubMed ID: 20211180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis.
    Hoshida Y; Villanueva A; Sangiovanni A; Sole M; Hur C; Andersson KL; Chung RT; Gould J; Kojima K; Gupta S; Taylor B; Crenshaw A; Gabriel S; Minguez B; Iavarone M; Friedman SL; Colombo M; Llovet JM; Golub TR
    Gastroenterology; 2013 May; 144(5):1024-30. PubMed ID: 23333348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data.
    Konerman MA; Zhang Y; Zhu J; Higgins PD; Lok AS; Waljee AK
    Hepatology; 2015 Jun; 61(6):1832-41. PubMed ID: 25684666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms Related to Iron Homeostasis Associate with Liver Disease in Chronic Hepatitis C.
    Wróblewska A; Woziwodzka A; Rybicka M; Bielawski KP; Sikorska K
    Viruses; 2023 Aug; 15(8):. PubMed ID: 37632052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights into hepatitis C.
    Forton DM; Wright M; Knapp S; Thursz MR; Taylor-Robinson SD; Thomas HC
    Clin Med (Lond); 2002; 2(6):554-9. PubMed ID: 12528970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibulin-4 as a potential extracellular vesicle marker of fibrosis in patients with cirrhosis.
    Kumagai M; Tsuchiya A; Yang Y; Takeda N; Natsui K; Natusi Y; Tomiyoshi K; Yamazaki F; Koseki Y; Shinchi H; Imawaka N; Ukekawa R; Nishibu T; Abe H; Sasaki T; Ueda K; Terai S
    FEBS Open Bio; 2024 Aug; 14(8):1264-1276. PubMed ID: 38853023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The roles and mechanisms of hypoxia in liver fibrosis.
    Cai J; Hu M; Chen Z; Ling Z
    J Transl Med; 2021 May; 19(1):186. PubMed ID: 33933107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Possible Role for TNF-α in Coordinating Inflammation and Angiogenesis in Chronic Liver Disease and Hepatocellular Carcinoma.
    Hammam O; Mahmoud O; Zahran M; Sayed A; Salama R; Hosny K; Farghly A
    Gastrointest Cancer Res; 2013 Jul; 6(4):107-14. PubMed ID: 24147158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Organelle stress and alterations in interorganelle crosstalk during liver fibrosis.
    Sinha S; Hassan N; Schwartz RE
    Hepatology; 2024 Feb; 79(2):482-501. PubMed ID: 36626634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with uncertain advanced fibrosis and cirrhosis diagnosis by Agile3+ and Agile4 scores cannot be excluded in validation studies.
    Ferreira LF; Mânica M; Villela Nogueira C; Tovo CV
    Hepatol Res; 2024 May; 54(5):495-496. PubMed ID: 38041561
    [No Abstract]   [Full Text] [Related]  

  • 20. TRPM5 rs886277 Polymorphism Predicts Hepatic Fibrosis Progression in Non-Cirrhotic HCV-Infected Patients.
    Resino S; Fernández-Rodríguez A; Pineda-Tenor D; Gómez-Moreno AZ; Sánchez-Ruano JJ; Artaza-Varasa T; Muñoz-Gómez MJ; Virseda-Berdices A; Martín-Vicente M; Martínez I; Jiménez-Sousa MA
    J Clin Med; 2021 Jan; 10(3):. PubMed ID: 33525598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.